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1. Introduction 
Cardiac troponin is the main regulatory protein of the thin filament and mediates the Ca2+-
sensitivity of the actin-myosin interaction. Troponin forms a heterotrimeric complex 
composed of the tropomyosin binding subunit (cTnT), the inhibitory subunit (cTnI) and the 
Ca2+-binding subunit (cTnC). A complex interplay between the cardiac troponin subunits 
and other thin filament proteins, as tropomyosin (Tm) and actin, is essential to regulate 
muscle contraction, which can be described by cross bridge cycling on the molecular level. 
Troponin is located on both sides of the thin filament with a stagger of about 27 Angstroms 
between two adjacent troponin molecules (Ebashi, 1972; Paul et al., 2009). In the thin 
filament each troponin binds to one tropomyosin, which covers 7 actin monomers. It is no 
surprise that mutations in genes encoding proteins, which participate in crossbridge cycling 
and its regulation, derange interactions and lead to contractile dysfunction and disease. In 
all three cardiac troponin subunits, changes in amino acid sequence have been identified in 
families with hypertrophic (HCM), restrictive (RCM) and dilated cardiomyopathy (DCM). 
Therefore knowledge of structure, function and interactions of the proteins is a prerequisite 
to understand dysfunction in disease. 
1.1 Cardiac troponin T (cTnT) 
One of the main tasks of cardiac troponin T (30-35kDa) is to fix the troponin complex to the 
thin filament. Furthermore cTnT participates in conferring calcium sensitivity to 
actin/myosin (Tobacman, 1988). Tobacman also showed that the N-terminal half of cTnT, 
TnT1 (amino acids 1-158, skeletal muscle numbering), was able to keep the thin filament in 
the blocked state without TnI. In the blocked state of the thin filament no interaction 
between actin and myosin is possible, i.e. no force production occurs. Thus cTnT plays an 
active role in inhibition of actin/myosin interaction in the resting state. It further promotes 
tropomyosin polymerization and binding of tropomyosin to actin.  
Structural information on cTnT is poor. According to EM analysis of thin filaments and low 
resolution co-crystallization of Tm in complex with cTnT, cTnT is highly asymmetric. It is a 
180-202 nm long comma –shaped molecule, with the N-terminal rod like part arranged 
along the thin filament and a C-terminal more globular domain (Ohtsuki, 1979, Flicker et al., 
1982, White et al., 1987). The high resolution crystal structure available for the core troponin 
complex contains only the less flexible C-terminal part of cTnT, which binds the other two 
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troponin subunits, cTnI and cTnC (Takeda et al., 2003). There is strong evidence from latest 
single particle reconstruction studies of the thin filament by Paul et al., (2009), that the N- 
terminal tail of cTnT points to the M-band of the sarcomere, whereas the core domain of the 
troponin complex is oriented versus the Z-band. 
The N-terminal tail fraction of cTnT contains a hypervariable N-terminal part and a highly 
conserved region, which is located in the central region of the cTnT molecule (Fig. 1). This 
conserved region contains the main interaction site for tropomyosin (Biesiadecki et al., 2007, 
Perry, 1998) comprising 39 amino acids (residues 98-136 (human cardiac sequence)) (Jin & 
Chong, 2010). The Tm interaction site forms a helix according to Murakami et al., (2008) and 
binds to the overlapping region of two tropomyosin molecules (Jin & Chong, 2010). Crystal 
structure of the tropomyosin overlap region and the Tm binding helix reveals the formation 
of a four helix bundle between tropomyosin ends and cTnT (Murakami et al., 2008). The 
hypervariable region of the cTnT tail fraction does not bind to tropomyosin and can be 
truncated without losing binding ability of the rest of the molecule (Zhang et al., 2006). 
Phylogenetically the hypervariable region might be added to the conserved core region of 
cTnT (Conserved tail region and C-terminal domain) (Jin & Samanez, 2001; Biesiadecki et 
al., 2007). Its function is not completely elucidated, but the hypervariable region may play a 
role as modulator of the core molecule thus subtly affecting binding affinities of Tm and 
cTnT (Biesiadecki et al, 2007; Feng et al., 2008).  
A second interaction site for tropomyosin is located at the beginning of the C-terminal half 
of cTnT and has lately been analysed by Jin & Chong (2010) using antibodies. They showed 
that highly conserved amino acid sequences are involved comprising amino acid residues 
197-236 (human sequence). This interaction site binds to the middle part of tropomyosin 
near Cys190. Earlier studies (Pearlstone et al., 1983; Morris & Lehrer, 1984) propose the 
second interaction with tropomyosin at the very C-terminus of cTnT involving residues 272-
288. Whichever amino acids are included in the cTnT/Tm interactions, in the presence of 
cTnC binding of the TnT-C-Terminus to tropomyosin near Cys190 is Ca2+ dependent 
(Chong & Hodges, 1982). Ca2+ weakens its binding to tropomyosin though the molecular 
mechanism, i.e. conformational changes which lead to alteration in Tm/TnT -binding, is not 
known yet. The TnT-C-Terminus also contains the binding site for the other two troponin 
subunits, TnI and TnC. According to the 3 D structure of the core cardiac troponin complex, 
the helix in the C-terminal region of cTnT (residues 226-271), which is highly conserved (Jin 
et al., 2008) forms a rigid coiled coil with a cTnI-helix (residues 90-136) and is part of a rigid 
structure within the troponin complex, called the IT-arm (Takeda et al., 2003). At the C-
terminal end of the coiled coil the interaction site for cTnC is located and comprises amino 
acid residues 256- 270. The organisation of cTnT is summarized in Fig.1.  
In cardiac muscle the mammalian cTnT- gene (TNNT2) is composed of 17 exons. Exon 5 is 
absent in adult cTnT (Cooper & Ordahl, 1985). Exon 5 encodes a 10 amino acid long region 
within the hypervariable N-terminus of cTnT. This sequence contains several acidic residues 
and contributes to a more negatively charged cTnT. Such a charge difference may modulate 
function. Indeed fetal cTnT, which contains exon 5, exhibits a higher Ca2+-sensitivity compared 
to adult cTnT and shows a higher tolerance towards acidic pH (Gomes et al., 2002). Mainly 4 
variants of human cTnT (cTnT1-4) have been described due to alternative splicing of exons 4 
and 5, whereby TnT1 and TnT3 are the major isoforms present in fetal and in the adult human 
cardiac muscle, respectively (Townsend et al., 1995; Anderson et al., 1991). The expression 
pattern of cTnT isoforms seems to be altered in heart failure and correlates with changes in 
Ca2+- sensitivity. The modification in Ca2+- sensitivity however, seems not to be caused by an 
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alteration in the isoform expression pattern. Differences in the phosphorylation status of 
sarcomeric proteins, especially of myosin light chain 2 (MLC-2) may be decisive (van der 
Velden et al., 2003). Also cTnT itself is a phospho protein (Fig. 1) which is constitutively 
phosphorylated at Ser1 in several species inclusive men due to the action of casein kinase- 2 
(Gusev et al., 1980; Risnik & Gusev, 1984, Swiderek et al., 1990). The function of this 
phosphorylation is not known up to date. It might prevent degradation and/or interaction of 
the hypervariable region. At least one further reversible phosphorylation site for PKC is 
located in the C-terminal region of cTnT near the second Ca2+- dependent interaction site for 
Tm and thus may affect Ca2+- sensitivity of the actin/myosin interaction. Indeed, according to 
Sumandea et al., reversible phosphorylation of Thr206 (mouse sequence) is critical for function 
(Sumandea et al., 2003). In vitro experiments showed that phosphorylation by PKCα decreases 
maximal tension, myofilament Ca2+ -sensitivity, actomyosin ATPase activity and cooperativity 
(Sumandea et al., 2003). Other protein kinases than PKC, as for example ROCKII (Vahebi et al., 
2005), phosphorylate cTnT in vitro. The physiological role of cTnT phosphorylation by 
different protein kinases is not yet clarified. cTnT, however, is not a target of cAMP dependent 
protein kinase (PKA), which is activated upon ß-adrenergic stimulation. But as recently 
described by Sumandea et al., (2011) cTnT forms an AKAP for PKA with either regulatory 
subunit I or II (PKA-RI, PKA-RII) and thus provides a platform for sarcomeric protein 
phosphorylation upon ß-adrenergic stimulation. Binding of PKA might occur within the 
amino acid region 202-226 which forms an amphiphilic helix needed for the docking of PKA 
RI and—II (Feliciello et al., 2001). The interaction site for PKA-R would then be located just 
near the second interaction site with tropomyosin described by (Jin & Chong, 2010) and the 
PKC phosphorylation site. This implies that PKA-R binding might be affected by PKC 
phosphorylation and vice versa. 
 
 
Fig. 1. Organisation , interaction and phosphorylation sites of cardiac troponin T. Exons 
known to contain cardiomyopathy mutations are indicated by numbers 
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1.2 Cardiac troponin C (cTnC) 
cTnC is the calcium binding subunit of the cardiac troponin complex. Structurally the 
protein belongs to the EF-hand calcium binding protein super family together with 
parvalbumin, the first described protein of this family, Calmodulin, skeletal muscle troponin 
C etc. cTnC is composed of two lobes connected by a flexible linker (Sia et al., 1997) (Fig.2). 
 
 
Fig. 2. Interaction sites and cardiomyopathy inducing single amino acid exchanges in cTnC 
The structure was taken from PDP 1AJ4 based on the work of (Sia et al., 1997). The 3 D 
structure of cTnC in calcium (green points) saturated from is shown. Helices are given as 
magenta ribbons. The position of cardiomyopathy mutations is indicated by stars. 
Interacting proteins are given in blue. 
Each lobe contains two parallel EF hands, each of which forms the helix-loop-helix divalent 
metal binding domain. Helices in a protein have been labeled by capital letters, with A 
assigned to the most N-terminally located helix. Thus E and F are the loop flanking helices 
in parvalbumin forming the metal binding motif. The name EF-hand for the helix loop helix 
metal binding motif is based on this nomenclature. The short helices of about 10-12 residues 
are arranged perpendicular. The loop is composed of 12 residues essential for calcium 
coordination in a pentagonal bipyramidal configuration. The residues 1, 3, 5, 7, 9 and 12 (X, 
Y, Z, -Y, -X, -Z) are involved in Ca2+-coordination. In position 12 there is a conserved 
glutamate or aspartate residue providing two oxygens for calcium binding (Structure 
Reference: PDB: 2PMY). The calcium binding residues preferentially have an acidic side 
chain, but also the protein backbone is involved. In cTnC the two EF hands (III, IV) in the C-
terminal lobe are the high affinity Ca2+-, Mg2+-binding sites, which contain metal ions also at 
low (relaxing) intracellular Ca2+-concentration. This C-terminal domain of cTnC provides 
the platform for binding of cTnI and of cTnT and therefore is pivotal for the integrity of the 
troponin complex. Helices of the metal bound C-terminal domain exhibit a hydrophobic 
pocket, where cTnI is bound (Gasmi-Seabrook et al., 1999). cTnT binds to Calcium sites III 
and IV at the end of the rigid coiled coil. Besides the structural role of the C-terminal lobe, 
there is now strong evidence that it plays an active part in thin filament activation (Fuchs & 
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Grabarek, 2011). Alteration in Ca2+-/Mg2+-binding to sites III and IV might alter the 
interaction with cTnT and the coiled coil structure. Also the identification of 
cardiomyopathy causing alterations in this part of cTnC points to the involvement in 
regulation. 
The N-terminal EF-hand I is not able to bind Ca2+ due to an insertion of Val and the 
replacement of two Asp residues involved in Ca2+-coordination by Ala and Leu residues. 
Therefore there is only one functional active Ca2+-binding site (site II) in the N-terminal 
domain of cTnC, which is a high affinity Ca2+-specific binding site. Binding and release 
kinetics of Ca2+ to cTnC within the thin filament are such that Ca2+-binding and release 
occurs within one contraction cycle (Davis & Tikunova, 2008). Saturation of cTnC with Ca2+ 
is obtained upon increase in intracellular Ca2+-concentration after influx from sarcoplasmatic 
Ca2+-store upon membrane depolarization. Therefore site II is named the regulatory Ca2+-
binding site. Due to the non functional site I there is no conformational switch from closed 
to open solely upon Ca2+ -binding as is observed for skeletal muscle TnC and the C-terminal 
lobe of cTnC (Sia et al., 1997). For the stabilization of the open conformation of the N-
terminal lobe cTnI binding is required (Dong et al., 1999; Li et al., 1999). There exist multiple 
interaction sites for cTnI throughout the complete cTnC molecule. The amphiphilic part of 
helix 1 in cTnI (residues 43-65) binds via several polar and van der Waals interaction to the 
C-terminal cTnC lobe and around residue 10 of the N-terminal helix of cTnC. Furthermore 
residues 93-161 in the C-terminal lobe of cTnC interact with the IT-arm (Takeda et al., 2003), 
The N-terminal lobe of cTnC forms the Ca2+-dependent binding site for the cTnI switch 
region (Takeda et al., 2003) and a phosphorylation dependent binding site near the 
nonfunctional Ca2+-binding loop with the flexible heart specific N-terminal cTnI extension 
(see below) (Schmidtmann et al., 2005).  
1.3 Cardiac troponin I (cTnI) 
cTnI, the inhibitory subunit of the troponin complex is a very flexible molecule consisting of 
helices and random coils. In solution cTnI exhibits no tertiary structure. A specific spatial 
orientation is only obtained within the ternary troponin complex. cTnI is build up in a 
modular fashion (Fig. 3).  
1.3.1 The N-terminal extension 
The N-terminal extension of about 31 amino acids (length is dependent on species) is heart 
specific and resembles the hypervaraible region of cTnT. It contains conserved amino acid 
stretches; thus at the very N-terminus there is a acidic region (Sadayappan et al., 2008) 
followed by a proline rich sequence, which forms a polyprolin helix and functions as a rigid 
spacer to keep the N-terminus extended (Howarth et al., 2007). Then the phosphorylation 
region follows, which contains two adjacent located serine residues at position 22 and 23 
(numbered without starter methionine). Both residues are substrates for PKA (Swiderek et 
al., 1990; Mittmann et al., 1990). In its dephosphorylated state the N-terminal cTnI arm 
interacts between residues 10-30 with cTnC around amino acid residue 29 (Fig. 2) (Finley et 
al., 1999; Gaponenko et al., 1999; Abbott et al., 2000; Ward et al.,2003, 2004; Schmidtmann et 
al., 2002, 2005). This interaction also seems to stabilize the open conformation of the cTnC-
N-terminal lobe (Abbott et al., 2000, 2001; Ward et al., 2004). Bisphosphorylation of the two 
serine residues 22 and 23 by PKA upon ß- adrenergic stimulation releases the interaction 
with cTnC. According to Howarth et al, (2007) the bisphosphorylated arm contains a helix 
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comprising amino acids 21-30 being stabilized by salt bridges between phosphate and 
preceeding arginine residues (Jaquet et al. 1998). The release of the extension from cTnC 
takes place due to the insertion of negative charges followed by conformational changes. 
This allows a different interaction, which is directed by the acidic part of the N-terminal 
cTnI arm and therefore needs a positively charged partner (Sadayappan et al., 2008). 
Clusters of basic amino acid residues are provided by the regulatory C-terminal domain of 
cTnI itself, but also an additional interaction with actin cannot be excluded. The release of 
the N-terminal arm from cTnC leads to a reduction of the Ca2+ -affinity of cTnC, in 
myofilament Ca2+-sensitivity (Zhang et al 1995; Reiffert et al., 1996) and to enhanced cross 
bridge cycling (Kentish et al.,2001; Turnbull et al., 2002). There is evidence that the main 
action occurs via interaction with cTnI, which stabilizes cTnI binding to the thin filament 
(Sakthivel et al., 2005). 
 
 
Fig. 3. Organization of cTnI, its interactions (blue) and phosphorylation sites (indicated by    )  
1.3.2 Constitutive cTnC and cTnT binding sites 
The cTnC binding site is located subsequent to the N-terminal extension. It forms a helix 
(helix 1 according to the nomenclature of Takeda et al., 2003) which contacts the N-terminal 
cTnC helix and reaches to the C-terminal lobe of cTnC. It strongly binds to the hydrophobic 
pocket of the C-terminal cTnC lobe. The C-terminal part of helix 1 also interacts with cTnT 
via several hydrogen bonds and hydrophobic interactions. This helix is followed by another 
helical binding site for cTnT (helix 2). Helix 2 forms a coiled coil with a helix located in the 
C-terminal half of cTnT. The two helices are part of the IT arm (Takeda et al., 2003). Both 
these binding sites in cTnI are independent on reversible Ca2+ -binding to the regulatory 
Ca2+ binding loop in cTnC. In helix 1 there are two serine residues (Ser43/45) which are 
phosphorylated by PKC upon alpha adrenergic stimulation. Ser43/45 are positioned near 
residue 10 of the N-terminal helix in cTnC-N-terminal lobe as well as near the C-terminal 
lobe. Thus, phosphorylation might alter these interactions. In mice phosphorylation of these 
sites by PKC upon α-adrenergic stimulation is responsible for the negative inotropic effect 
and might be influenced by the cTnT phosphorylation state. The physiological effect of PKA 
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dependent phosphorylation at Ser22/23 seems not to be impaired by Ser43/45 
phosphorylation (Montgomery et al., 2002).  
1.3.3 Regulatory C-terminal region 
The C-terminal region of cTnI can functionally be subdivided into the inhibitory region 
comprising amino acids 137-148, the helical switch region (amino acids 150-159) and the C-
terminal mobile region. The inhibitory region binds to actin/tropomyosin in the relaxed 
state, i.e. when the regulatory Ca2+ binding loop of cTnC contains no Ca2+. Within this region 
there is another heart specific PKC phosphorylation site at Thr 144. The physiological role of 
this phosphorylation site is not quite clear (Solaro & Kobayashi, 2011), though investigations 
by Tachampa et al., (2007) imply that Thr144 is involved in length dependent activation of 
tension development in thin filament bundles. Phosphorylation might modulate this 
function probably by loosening the interaction of cTnI inhibitory region with actin.  
Upon Ca2+- saturation of cTnC the inhibitory region is released from actin and the switch 
region binds to the cTnC-N-terminal lobe inducing the formation of the hydrophic pocket. 
Strength of interaction is sensible to small conformational changes in the cTnC-N-lobe also 
affecting Ca2+-binding affinity. The C-terminal mobile region following the switch region is 
a very important cTnI region for regulation of muscle contraction, though not much is 
known about this region. It provides a second actin binding site and a tropomyosin binding 
site. Under relaxing conditions, this mobile region is fixed to tropomyosin (Pirani et al., 
2005; Galinska et al., et al., 2008) and actin, and is released from actin/tropomyosin upon 
Ca2+-saturation of cTnC. Thus the C-Terminus stabilizes the blocked state of the thin 
filament (Galinska et al., 2010). Probably this effect is intensified by the interaction of cTnT 
binding to tropomyosin actin. Thus cTnT- N-terminus and cTnI-C-terminus both support 
the inhibitory region of cTnI in keeping tropomyosin in the blocking position. Hereby 
troponin complexes on opposite sites cooperate, one complex providing cTnT/tropomyosin 
interaction the other cTnI/tropomyosin/actin interaction (Paul et al., 2009; Solaro & 
Kobayashi, 2011). But cardiac TnI is not only involved in regulation of inhibition, but also of 
activation. Evidence came from investigations of Galinska et al., (2010) using truncated cTnI 
and normal length cTnI. They showed that the C-terminus is also involved in stabilization of 
tropomyosin in the active state (Ca2+ - saturated cTnC). Truncation may occur in vivo due to 
proteolysis in myocardial stunning (reversible ischemia/reperfusion injury) (Foster et al., 
2003) and due to cardiomyopathy mutations. 
2. Cardiomyopathy inducing troponin mutations 
A large number of mutations have been detected in genes encoding for the three cTn 
subunits in patients suffering of cardiomyopathies (tables 1-6). Resulting phenotypes are 
highly variable, even within a family carrying the same mutation (see below), indicating 
that modifiers, environment or polymorphisms are involved in disease development. Wang 
et al., (2005) was the first group who detected a polymorphism in the MYBPC3 (cardiac 
myosin binding protein C gene) that might be able to modify the expression of hypertrophy. 
Also combinations of more than one mutation determine the disease development. 
Therefore it is still impossible to correlate phenotype and genotype, though an immense 
progress has been made in the understanding of molecular pathogenesis. The goal to 
understand phenotype development remains. Since the disease is primarily caused by 
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mutations, it is crucial to improve knowledge on the dysfunctions on molecular level in 
detail of as many mutants as possible. Thus one might be able to detect common features 
and mechanisms which might allow detection of a link to phenotype development. Though 
the molecular effects of only a couple of mutations have been thoroughly investigated a first 
common rule, namely an enhancement in Ca2+- sensitivity of the myofilament for 
HCM/RCM-mutants and a decrease in Ca2+- sensitivity for DCM mutants has been stated 
by Robinson et al., (2007). However it seems to be too simple and does not explain the 
development of HCM or RCM or the often very low degree of hypertrophy despite large 
Ca2+ sensitivity changes and susceptibility to malignant arrhythmia. Furthermore, the rule 
does not apply to all mutations investigated. One problem is that analysis of Ca2+ -
sensitivity resulted in many opposing statements. Thus for example Nakaura et al., 1999 did 
not observe enhanced Ca2+ -sensitivity of force in skinned fibres with cTnT-F110I, whereas 
Hernandez et al., 2005 described enhanced Ca2+ -sensitivity of force development as well as 
of actomyosin ATPase activity. One main reason lies in the complexity of the systems used, 
as reconstituted proteins, skinned fibers, myofibrils, isolated cardiomyocytes (adult or 
neonatal), transgenic animals. In general results obtained with higher organised system 
sseem to be more reliable. But additionally species differences might account for differing 
results. For example according to Rust et al., (1999) overexpression of cTnT-I79N in rat 
cardiomyocytes resulted in suppressed contractile performance, whereas others using mice 
myofibrils suggested hypercontractility.  
2.1 Mutations in TNNT2, the gene encoding cTnT 
Most mutations in TNNT2 detected in patients lead to familial hypertrophic 
cardiomyopathy (HCM), only a few to restricted cardiomyopathy (RCM) or dilated 
hypertrophic cardiomyopathy (DCM) (Table 1). Families with DCM mutations in TNNT2 
mostly exhibit a severe disease progression with poor prognosis.  
2.1.1 HCM inducing mutations 
HCM-mutations in TNNT2 are found in about 10% of the HCM cases, and thus TNNT2 
belongs to the more abundant troponin disease genes. There is no known HCM mutation 
which is located within the hypervariable N-terminal region of cTnT. All mutations 
identified in patients suffering from HCM are located either near or within the N-terminal 
main interaction site for tropomyosin (amino acids 79-182) or within the C-terminal half 
(amino acids 203-288) which contains multiple interaction and putative phosphorylation 
sites (Table 1; Fig. 1). This distribution of mutations implies that they affect the interaction 
either with tropomyosin (Tm) and/ or the other troponin subunits and might influence 
phosphorylation dependent effects. The majority of gene loci, where mutations have been 
identified in patients encode the N-terminal region of cTnT interacting with the overlap of 
Tm (Table 1; Fig. 1). Mutations in the Tm binding region of cTnT (amino acids 92-183) 
destabilize Tm binding to actin filaments (Palm et al., 2001). Mutations within the main Tm 
binding site further weaken the end-to-end Tm interaction, which is responsible for the 
cooperativity (Palm et al., 2001). Also a lowered affinity of troponin to actin/Tm could be 
expected. Indeed cTnT-F110I, located at the C-terminal end of the main Tm binding region, 
impairs binding of troponin to actin/Tm by altering the dynamic properties of the tail 
region (Hinkle & Tobacman, 2002). It reduces its flexibility. Flexibility of the cTnT-tail is an 
important feature for its interaction with Tm overlap region (Hinkle & Tobacman, 2002). 
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Mutation Disease Exon/Intron Reference 
Phe70Leu (F70L) HCM 8 Richard et al., (2003) Circ. 107: 2227-32 
Pro77Leu (P77L) HCM 8 Varnava et al., (2001) Circ. 104: 1380-4 
Ile79Asn (I79N) HCM , RCM, DCM 8 
Thierfelder et al., (1994) Cell 77:701-12; 
Watkins et al., (1995) NEJM. 332: 1058-64; Rust 
et al., (1999) JCI. 104: 1459-67; Yanaga et al., 
JBC. (1999) 74:8806-12; Varnava et al., (2001) 
Circ. 104: 1380-4 ; Palm et al., (2001) Biophys J. 
81: 827-37 ; Westermann et al., (2006) Eur J 
Heart Fail. 8:115-21 ; Menon et al., (2008) Clin 
Genet, 74(5): 445-54 ; Baudenbacher et al.,(2008) 
JCI. 118 :3893-903 ; Midde et al., (2011) JMCC 
[Epub ahead of print] 
Glu83Lys (E83K) HCM 8 Mogensen et al., (2003) J Med Genet 40: e59 
Val85Leu (V85L) HCM 8 Konno et al., (2005) J Intern Med. 258: 216-24. 
Asp86Ala (D86A) HCM 8 Van Driest et al., (2003) Circ. 108: 445-51 
Arg92Trp (R92W) HCM 9 
Moolman et al., (1997) JACC. 29: 549-55; 
Moolman-Smook et al., (1999) Am J Hum 
Genet. 65:1308-20; Fujino et al., (2001) Clin 
Cardiol. 24: 397-402; Varnava et al., (2001) Circ. 
104:1380-4; Palm et al., (2001) Biophys J. 
81:2827-37; Waldmuller et al., Hum Mutat 
(2002) 19:560-9; Ackerman et al., (2002) JACC. 
39: 2042-8; Van Driest et al., (2003) Circ. 108: 
445-51; Shimizu et al., (2003) Clin Cardiol 26: 
536-9; Konno et al., (2005) J Intern Med. 
258:216-24 
Arg92Leu (R92L) HCM 9 
Forissier et al., (1996) Circ. 94: 3069-73 ; 
Varnava et al., (2001) Circ. 104: 1380-4 ; Palm et 
al., (2001) Biophys J. 81:2827-37 ; Richard et al., 
(2003) Circ. 107: 2227-32 
Arg92Gln (R92Q) HCM 9 
Thierfelder et al., (1994) Cell 77:701-12; 
Watkins et al., (1995) NEJM. 332:1058-64; 
Yanaga et al., (1999) JBC. 274: 8806-12; Palm et 
al., (2001) Biophys J. 81:2827-37 ; Cuda et al., 
(2002) Hum Mutat 19:309-10; Robinson et al., 
(2002) JBC. 277: 40710-6; Hinkle & Tobacman 
(2003)JBC. 278: 506-13; Javadpour et al., (2003) 
JCI. 112: 768-75; Torricelli et al., (2003) Am J 
Cardiol 92:1358-62; Van Driest et al., (2004) 
JACC. 44: 1903-10 
Arg94Leu (R94L) HCM 9 
Varnava et al., (1999) Heart 82: 621-4; Varnava 
et al., (2001) Circ. 104:1380-4 ; Palm et al., (2001) 
Biophys J. 81:2827-37 
Arg94Cys (R94C) HCM 9 Mogensen et al., (2003) J Med Genet. 40: e59 
Lys97Asn (K97N) HCM 9 
Barr, Seidman et al., (2001) originally posted on 
URL: http://www.cardiogenomics.org 
Ala104Val (A104V) HCM 9 
Nakajima-Taniguchi et al., (1997) JMCC. 29: 
839-43; Palm et al., (2001) Biophys J. 81: 2827-
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Mutation Disease Exon/Intron Reference 
Phe110Ile (F110I) HCM 9 
Watkins et al., (1995) NEJM. 332: 1058-64; Anan 
et al., (1998) Circ. 98: 391-7; Yanaga et al., 
(1999) JBC. 274: 8806-12; Lin et al., (2000) 
Cardiol. 93:155-62 ; Palm et al., (2001) Biophys 
J. 81: 2827-37 ; Hinkle & Tobacman (2003) JBC. 
278: 506-13; Konno et al., (2005) J Intern Med. 
258: 216-24; Hernandez et al., (2005) JBC. 280: 
37183-94 
Phe110Leu (F110L) HCM 9 Torricelli et al., (2003) Am J Cardiol. 92: 1358-62 
Phe110Val (F110V) HCM 9 
Richard et al., (2003) Circ. 107: 2227-32 ; 
Torricelli F et al., (2003) Am J Cardiol. 92: 1358-
62 
Lys124Asn (K124N) HCM 9 
An et al., (2004) Zhonghua Xue Za Zhi 84:1 
340-3 
Arg130Cys (R130C) HCM 10 
Torricelli et al., (2003) Am J Cardiol. 92: 1358-
62 ; Song et al., (2005) Clin Chim Acta 351: 209-
16 
Glu163Lys (E163K) HCM 11 
Watkins et al., (1995) NEJM. 332: 1058-64; Palm 
et al., (2001) Biophys J. 81: 2827-37 
Glu160del (ΔE160) HCM 11 
Watkins et al., (1995) NEJM. 332: 1058-64; Palm 
et al., (2001)Biophys J. 81: 2827-37 ; Richard et 
al., (2003) Circ. 107: 2227-32 ; Mogensen et al., 
(2003) J Med Genet. 40:e59; Torricelli et al., 
(2003) Am J Cardiol. 92:1358-62; Capek & 
Skvor (2006) Meth Inf Med. 45: 169-72 
Ser179Phe (S179F) HCM 11 Ho et al., (2000) Circ. 102:1950-5 
Glu244Asp (E244D) HCM 14 
Watkins et al., (1995) NEJM. 332: 1058-64; 
Yanaga et al., (1999) JBC. 274: 8806-12; Moore, 
Seidman et al., (2004) URL: 
http://www.cardiogenomics.org 
Lys247Arg (K247R) HCM 14 
Garcia-Castro et al., (2003) Clin Chem. 49: 
1279-85 
Asn271Ile (N271I) HCM 15 Richard (2003) Circ. 107:2227-32 
Lys273Glu (K273E) HCM 15 
Fujino et al., (2002) Am J Cardiol. 89:29-33; 
Venkatraman et al., (2003) JBC 278: 41670-6; 
Konno et al., (2005) J Intern Med. 258: 216-24 
IVS15+1G>A HCM 15 
Thierfelder et al., (1994) Cell 77: 701-12; 
Watkins et al., (1995) NEJM. 332: 1058-64; 
Watkins et al., (1996) JCI. 98: 2456-61. ; 
Mukherjea et al., (1999) Biochem. 38: 13296-301; 
Redwood et al., (2000) Circ Res. 86: 1146-52; 
Varnava et al., (2001) Circ. 104: 1380-4 
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Mutation Disease Exon/Intron Reference 
Arg278Cys (R278C) HCM 16 
Watkins et al., (1995) NEJM. 332:1058-64; 
Yanaga et al., (1999) JBC. 274:806-12; Elliott et 
al., (1999) NEJM. 341: 1855-6; Barr, Seidman et 
al., 2002 and Moore, Seidman et al., (2003, 
2004) URL:http://www. cardiogenomics.org; 
Van Driest et al., (2003) Circ. 108: 445-51; 
Garcia-Castro et al., (2003) Clin Chem 49: 1279-
85; Garcia-Castro et al., (2003) Rev Esp Cardiol. 
56: 1022-5; Torricelli (2003) Am J Cardiol 92: 
1358-62; Theopistou et al., (2004) Am J Cardiol 
94: 246-9; Miliou et al., (2005) Heart 91: 966-7; 
Hernandez et al., (2005) JBC. 280:371 83-94; 
Ingles et al., . (2005) J Med Genet. 42:e59, 
Sirenko et al., (2006) J Physiol. 5755.1: 201-13 
Arg278Pro (R278P) HCM 16 
Erdmann et al., 1998. (on-line); Van Driest et 
al., (2003) Circ. 108: 445-51; Miliou et al., (2005) 
Heart 91: 966-7 
Arg286Cys (R286C) HCM 16 
Richard et al., (2003) Circ. 107: 2227-32 ; Miliou 
et al., (2005) Heart 91: 966-7 
Arg286His (R286H) HCM 16 
Van Driest et al., (2003) Circ. 108: 445-51 ; Van 
Driest et al., (2004) JACC. 44: 1903-10 
Trp287ter 
(W287ter) 




Mogensen et al., (2004) JACC. 44: 2033-40 ; 




Li et al., (2001) Circ. 104:2188-93 ; Venkatraman 
et al., (2003) JBC. 278: 41670-6 ; Villard et al., 
(2005) EHJ. 26: 794-803 ; Mirza et al., (2005) 
JBC. 280 :28498-506 
Ala172Ser (A172S) DCM 11 
Stefanelli et al., (2004) Mol Genet Metab. 83: 
188-96 
Arg205Leu (R205L) DCM 13 
Mogensen et al., (2004) JACC 44: 2033-40; 
Mirza et al., (2005) JBC. 280 :28498-506 
Lys210del (ΔK210) DCM 13 
Kamisago et al., (2000) NEJM. 343: 1688-96; 
Hanson et al., (2002) J Card Fail. 8 : 28-32 ; 
Venkatraman et al., (2003) JBC 278: 41670-6 ; 
Mogensen et al., (2004) JACC 44: 2033-40. 
Asp270Asn 
(D270N) 
DCM 15 Mirza et al., (2005) JBC. 280 :28498-506 
Glu96del (ΔE96) RCM 9 Peddy et al., (2006) Pediatrics 117:1830-3; Pinto 
et al., (2008) JBC. 283:2156-66 
Asn100del/Glu101 
Del (ΔN100/ΔE101) RCM 9 
Pinto et al., (2011)JBC 286:20901-12 (double 
mutation) 
Glu136Lys (E136K) RCM 10 Kaski et al., (2008) Heart 94:1478-84 
Updated from: Genomics of Cardiovascular Development, Adaptation, and Remodeling. NHLBI 
Program for Genomic Applications, Harvard Medical School. [june, 2011 accessed] and OMIM database. 
ter designates termination of sequence resulting in a truncated protein, del and Δ are synonyms for a 
deleted amino acid. The one letter code is given in brackets. 
Table 1. Mutations in TNNT2 
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Since the cTnT- N-terminus contributes to the inhibition of the actin/myosin interaction 
(Tobacman, 1988), one might assume that also inhibition is affected by mutations. Indeed 
inhibition of is reduced due to cTnT-F110I (Knollmann & Potter, 2001; Gomes et al., 2004). A 
similar decrease in inhibition has been described for I79N (Yanaga et al., 1999), though this 
amino acid exchange is positioned N-terminally of the main Tm interaction site. 
Nevertheless I79N and F110I exhibit several similarities. Thus, Midde et al., 2011 showed 
that rigor crossbridges in I79N or F110I containing filaments were disordered, indicating 
that disruption in thin filament structure may lead to severe contractile dysfunction. I79N, 
as most investigated HCM mutants, enhances the Ca2+- sensitivity of force development and 
actomyosin ATPase activity, which might contribute to enhanced contractility and higher 
energy consumption (Lin et al., 1996; Sweeney et al., 1998; Chandra et al., 2005). 
Furthermore, mouse hearts with I79N or R92Q could not increase cardiac performance upon 
ß-adrenergic stimulation (Knollmann et al., 2001; Javadpour et al., 2003), performance of 
I79N transgenic even worsened upon isoproterenol treatment (Sirenko et al., 2006). Such an 
effect as well as Ca2+ –sensitivity increase has not been observed with a R278C, a mutation 
located in the cTnT-C-terminus. These findings suggest that the region around amino acids 
79 and 92 is important for Ca2+ -signal transmission and affects Ca2+-regulation. 
Furthermore dysfunction is especially prominent under ß-adrenergic stimulation, which 
might explain the high risc for cardiac sudden death of these mutations. Causality between 
enhanced Ca2+-sensitivity and the potential for the development of malignant arrhythmias 
has been shown by Baudenbacher et al., (2008) for I79N. They described altered action 
potential duration due to the mutation. 
Mutations in TNNT2 gene encoding the C-terminal half of cTnT might affect the interaction 
with tropomyosin at the second Ca2+ -dependent binding site, as well as binding to cTnI and 
cTnC. Most mutations in this part lead either to single amino acid exchanges, deletions of 
single amino acids or to C-terminally truncated cTnT molecules due to splice site mutations. 
IVS15+1G>A is a splicing donor mutant which might result in two truncated proteins. In one 
mutant exon 16 is skipped encoding the C-terminal 14 amino acids, in the other mutants seven 
amino acids replace the C-terminal 28 amino acids encoded by exon 15 and 16 (Thierfelder et 
al., 1994). Both mutants are able to form a heterotrimeric troponin complex, however their 
affinity towards cTnI is drastically reduced (Mukherjea et al., 1999). The impaired interaction 
with cTnI may be the cause for reduced inhibitory capacity of troponin at low Ca2+- 
concentrations described by Redwood et al., (2000) and accelerated cross bridge kinetics 
(Stelzer et al., 2004). Furthermore a reduced binding of troponin to the thin filament has been 
reported dependent on its regulatory states (Knollmann & Potter, 2001; Burhop et al., 2001), 
indicating that the C-terminal part of cTnT stabilizes binding of cTn to the thin filament and 
affects Ca2+ -regulation. Increased Ca2+-sensitivity and cooperativity (Nakaura et al., 1999)) and 
impaired switching off myosin cycling at low Ca2+-concentrations is observed (Burhop et al., 
2001). Up to date nearly nothing is known on how cardiomyopathy inducing mutations in 
TNNT2 influence phosphorylation dependent effects of PKC dependent cTnT or PKA 
dependent cTnI phosphorylation. According to a study of Nakaura et al., (1999) effects of 
truncated cTnT were independent on PKA dependent cTnI phosphorylation.  
2.1.2 RCM inducing mutations 
There are only few RCM mutations detected in TNNT2 (Table 1). Most RCM mutations in 
genes encoding for cardiac troponin subunits are found in TNNI3 (see below). However, 
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interestingly I79N, originally listed as HCM mutation, might also cause RCM or DCM even 
in members of the same family. This indicates that other factors besides the mutation, as for 
example polymorphisms etc. (see below) are determinant for the development of the specific 
disease. Also in mice RCM might be evolved by I79N (Table 1). The other two RCM 
mutations (Table 1), a deletion of an acidic residue (E96del) and replacement of a glutamic 
acid residue by a basic lysine (E136K) have been detected in children developing RCM with 
very poor prognosis. E96del poorly inhibited actomyosin activity at low Ca2+ -
concentrations (Pinto et al., 2008) confirming that the cTnT N-terminus is important for the 
inhibitory capacity of the cardiac troponin complex. A first double deletion (Table 1) leads to 
the deletion of two amino acids, located adjacently within the main Tm binding site. In 
filaments with adult, not fetal cTnT an increase in Ca2+-sensitivity and decrease in 
cooperativity has been observed so far (Pinto et al., 2011). 
2.1.3 DCM inducing mutations 
Patients with DCM mutations in cTNNT2 exhibit a malignant prognosis as do also most of 
the FHC mutations in cTNNT2. Investigations on molecular level are largely missing to 
date. All patients showed decreased cardiac function (Kamisago et al., 2000) in contrast to 
enhanced contractility often observed in patients and transgenic animals carrying HCM 
mutations. In accordance in vitro analysis of DCM-mutations revealed a decreased Ca2+-
sensitivity (Mirza et al., 2005). Venkatraman et al., 2005 showed that ΔK210, the most 
prominent example for DCM causing cTnT-variation, decreases Ca2+-sensitivity of force and 
actomyosin ATPase activity as well as maximal force and ATPase activity not only with 
adult, but also with fetal cTnT. The deletion of K210 occurs in the second Ca2+ -sensitive 
tropomyosin binding region near the PKC phosphorylation site and possibly near the 
binding site for PKA regulatory subunit II. This implies that Ca2+ -regulation as well as PKC 
dependent phosphorylation of cTnT and/or PKA dependent phosphorylation of other 
sarcomeric proteins might be affected. Detailed information is missing.  
2.2 Mutations in TNNC1, the gene encoding cTnC 
Mutations in the TNNC1 gene occur seldom. Far less than 1% of the genetic disorders 
leading to familial cardiomyopathies in patients are due to mutations in TNNC1. Up to date 
only six HCM and one DCM inducing mutations, all single amino acid exchanges, have 
been identified (Fig.2; Table 2). A8V, L29Q and C84Y are located in the N-terminal and 
N122fs, E134D, D145E and G159D in the C-terminal domain of cTnC (Fig. 2). L29Q was the 
first mutation detected in the cTnC gene (Hoffmann et al., 2001). Since there was only one 
family showing this mutation, it is not clear if this mutation causes HCM. However, 
according to Schmidtmann et al., 2005 and Liang et al., 2008 this amino acid replacement has 
the potential to cause a cardiomyopathy. Replacement of leucine by glutamine destabilizes 
the interaction of the N-terminal cTnI arm with cTnC (Schmidtmann et al., 2005; 
Baryshnikova et al., 2008). The release of the N-terminal cTnI arm occurs also upon 
bisphosphorylation of cTnI after ß-adrenergic stimulation and contributes to a reduction in 
Ca2+-sensitivity of the actomyosin ATPase activity (see below). Consistent with this effect for 
L29Q a small reduction of Ca2+- sensitivity has been described (Schmidtmann et al., 2005). 
However, in the phosphorylated state of cTnI, an enhanced Ca2+-sensitivity of the 
actomyosin ATPase activity was observed, indicating an altered ß-adrenergic 
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mutation disease exon reference 
Leu29Gln (L29Q) HCM 3 
Hoffmann et al., (2001). Hum. 
Mutat. 17: 524; Dweck et al., 
(2008). J Biol Chem. 283: 33119-
28; Liang et al., (2008). Physiol. 
Gen. 33:257-66; Schmidtmann et 
al., (2005). FEBS J. 272(23):6087-
97. 
Ala8Val (A8V) HCM 1 
Landstrom et al., (2008). JMCC 
45: 281-288 ; Pinto et al., (2009) 
JBC. 284(28):19090-100; Pinto et 
al., (2011).JBC. 286(2):1005-13. 
Cys84Tyr (C84Y) HCM 4 
Landstrom et al., (2008). JMCC 
45: 281-288. 





Chung et al., (2011) Cardiol. 
Young [Ehead of print] 
Glu134Asp (E134D) HCM  
Pinto et al., (2009) JBC. 
284(28):19090-100 
Asp145Glu (D145E) HCM 5 
Landstrom et al., (2008). JMCC 
45: 281-288. 
Pinto et al., (2009) JBC. 
284(28):19090-100; Pinto et al., 
(2011).JBC. 286(2):1005-13. 
Gly159Asp (G159D) DCM 6 
Mogensen et al., (2004). JACC 
44: 2033-2040; Mirza et al., 
(2005). JBC 280: 28498- 506. 
Modified from: OMIM database (http://omim.org); the one letter code is given in brackets; fs 
designates frameshift. 
Table 2. Mutations in TNNC1 
(Dweck et al., 2008). Thus, in a higher organized system, namely mouse cardiomyocytes, 
Liang et al. (2008) described an enhanced Ca2+-sensitivity of force generation dependent on 
sarcomere length. They showed that also Ca2+- binding affinity to site II was higher in cTnC-
L29Q than in cTnC wild type, whereas Ca2+-dissociation rate was not affected. This is in 
agreement with former findings of Gillis et al., 2005, that residues 2, 28-30 affect Ca2+-
binding properties of the regulatory Ca2+-binding site. Replacement of these residues might 
increase cardiomyocyte contractility. Also the other FHC mutation in TNNC1, leading to 
A8V, C84Y and D145E replacements in cTnC, enhance Ca2+ -sensitivity of force 
development (Landstrom et al., 2008). For E134D no influence on Ca2+-sensitivity could be 
observed. It remains unclear how this mutation leads to contractile dysfunction. Since E134 
is located near contact sites of cTnI around Ser43/45 effects of PKC dependent 
phosphorylation might be influenced. Also A8V in the N-terminal helix of cTnC- N-lobe is 
located near a contact site with cTnI- Ser43 in H1 of cTnI (Li et al., 2004, Takeda et al., 2003). 
No data on the impact of these mutations on PKC phosphorylation are available up to date. 
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The proximity of A8 and E134 to the same cTnI region underlines findings of Smth et al. 
(1999) that the cTnC-N-terminal helix is spatially near the C-lobe. Latest kinetical 
investigations by Pinto et al, (2011a) showed that Ca2+ off rates are delayed for A8V and 
D145E, both stabilizing cross bridges. Thus structural disturbances at the cTnC-N-terminus 
not only alter structure of the N- but also of the C-terminal lobe and vice versa and may 
impair cTnC-cTnI interaction. C84Y is located at the end of the EF hand helix flanking 
regulatory Ca2+- binding loop at the transition to the central linker region. This residue 
probably is involved in forming the binding platform for the cTnI switch region and thus 
might destabilize binding of cTnI in Ca2+ -saturated state of cTnC (Fig. 2). D145E is located 
in Ca2+ -binding loop IV, in +Z position (see above) indicating that divalent cation binding 
might be affected (Pinto et al., 2009). Another amino acid exchange in the C-terminal lobe, 
G159D, is linked to DCM. Consistent with all other investigated DCM causing mutations 
G159D reduces Ca2+-sensitivity of the actin-myosin interaction and decreases contractility 
(Mirza et al., 2005). The hydrophobic residues at position 156,157 and 160 make contact to 
cTnI (Gasmi-Seabrook et al., 1999). Thus the G156D exchange may considerably disturb the 
hydrophobic interaction with cTnI and also might affect interaction with cTnT. In the 
troponin complex G159D reduced the opening (Ca2+ binding) and closing rates (Ca2+ 
dissociation) of the N-terminal domain of cTnC. Alteration in opening rate was also 
observed for L29Q, indicating that both mutants alter structural transition kinetics (Dong et 
al., 2008). PKA dependent phosphorylation of cTnI also affects kinetics in that it enhances 
the closing rate. This effect was abolished by L29Q and G159D implying that 
phosphorylation signal transduction is impaired as was earlier proposed for L29Q by 
Schmidtmann et al. (2005). 
2.3 Mutations in TNNI3, the gene encoding cTnI 
Most mutations in the gene encoding cTnI, are located in exon 7 and 8, which encode the 
regulatory C-terminal region of cTnI a few are located in the N-terminal heart specific 
extension. In patients they mostly induce either HCM or RCM. There are only three 
mutations identified up to date in TNNI3, which are linked to DCM. 
2.3.1 Mutations in TNNI3 linked to HCM 
Only one mutation has been identified in exon 3 encoding part of the heart specific N-
terminal cTnI arm (Table 3). This mutation results in an R20C (numbering without starter 
methionine) amino acid exchange, which is located within the consensus sequence for 
PKA (Fig. 3). The consensus sequence is present in cTnI in a dublicated form (Mittmann et 
al., 1992) enabling phosphorylation of two adjacent located serine residues (Ser22, 23) by 
PKA (Fig. 4). The exchange of the middle arginine in a series of three arginine residues 
(position 20 or 21 dependent on the inclusion of the starter methionine) impairs 
phosphorylation of the two serine residues and reduces the phosphorylation effect in vitro 
as shown by Gomes et al. (2005). Since both phosphorylation sites are affected, 
susceptibility towards proteolysis is enhanced. Phosphorylation protects to a certain 
extent towards proteolysis (Barta et al., 2003). But also the amino acid exchange itself 
might enhance susceptibility towards protein degradationas proposed by Gomes et al. 
(2005). Thus probably impairment of PKA dependent phosphorylation as well as 








*Designates phosphorylation sites, arg 20 is indicated 
Fig. 4. Consensus sequence in cTnI for PKA.  
The first 6 mutations in TNNI3 causing HCM were described by Kimura et al. (1997) (Table 
3). R145G, for example, is located within the inhibitor region of cTnI, which binds to 
actin/tropomyosin at low intracellular Ca2+ -concentrations (relaxed state) and blocks 
actin/myosin interaction (Fig. 3). Mutations located in the inhibitory region most probably 
affect inhibitory capacity of cTnI by altering actin/cTnI interaction in the relaxed state. 
Indeed R145G in fibers resulting from transgenic mice reduce inhibition (James et al., 2000; 
Wen et al., 2008) and binding affinity towards actin. Ca2+ -sensitivity of force development 
in skinned papillary muscles from these mice was enhanced with maximal force being 
decreased (Krüger et al., 2005; Wen et al ., 2008). These findings are in accordance with 
enhanced Ca2+-sensitivity and reduced maximal actomyosin ATPase activity described by 
Deng et al. (2001). Also energy consumption in transgenic mice was increased as shown by 
Wen et al., 2008, indicating hypercontractility. In isolated rat cardiomyocytes as in 
myofibrils from transgenic mice contractile parameters were reduced (James et al., 2000; 
Kruger et al., 2005; Reis et al., 2008) and Ca2+ -regulation and ß -adrenergic response was 
impaired (Lang et al., 2002; Reis et al., 2008). The dynamic properties of contraction were 
severely suppressed upon ß- adrenergic stimulation (Reis et al., 2008). This again supports 
the idea that impairment of ß- adrenergic signaling might be important for disease 
development. Furthermore, R145G might also affect PKC dependent phosphorylation at 
Thr144, which has not been investigated thoroughly yet. Kobayashi et al. (2004) showed that 
effects of exchange of all PKC sites Thr144/ Ser43/45 by a glutamic acid residue, which is 
thought to mimic phosphorylation, are reduced due to the mutation. Pseudophosphorylated 
PKC sites reduce the Ca2+ -dependent opening of the N-terminal lobe of cTnC (Kobayashi et 
al., 2004). However, a more differentiated analysis is needed.  
Mutations in the switch region (Table 3, Fig. 3), which binds to the N-terminal lobe of cTnC 
upon Ca2+-saturation, are thought to impair binding to N-terminal lobe of cTnC under Ca2+- 
saturating conditions. Thus, they probably affect Ca2+- dissociation from cTnC and the 
conformational switch of cardiac troponin I needed for transmission of the Ca2+- signal. An 
example for such a mutation is Ala157Val. 
Mutations located in the mobile C terminal cTnI region may alter cTnI Tm/actin interaction. 
This may affect inhibition as well as activation. The mobile C-terminus together with N-
terminal part of cTnT of the opposing troponin complex stabilizes the tropomyosin position 
in the blocked state. Indeed for C-terminally truncated cTnI impaired relaxation kinetics, 
enhanced Ca2+ sensitivity and disturbed cooperativity has been observed (Narolska et al., 
2006, Tachampa et al., 2009). A small decrease in inhibitory capacity has been described for 
R162W and K185del (Redwood et al., 1998). Mutations located at the very C-terminus of 
cTnI as G203S or K206Q do not exhibit an effect on inhibition (Deng et al., 2003, Köhler et al, 
2003). Again there are conflicting results concerning Ca2+-sensitivity alterations. Transgenic 
mice with cTnI-G203S exhibit altered Ca2+ -regulation and show prominent altered 
expression of cytosketetal, contractile proteins and of proteins involved in energy 
production (Tsoutsman et al., 2006; Lam et al., 2007). Not much is known about other 
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mutations at the same position, G203R (replacement of glycin by the positively charged 
larger and less flexible amino acid arginine) and a frameshift (fs) mutation (table 3). One 
would expect that dysfunction due to these sequence alterations are more prominent than 
for G203S. Also K206Q is not well characterized. It enhances maximal actomyosin ATPase 
activity and alters dynamics of the actin myosin interaction (Deng et al., 2003). According to 
our own latest investigations (abstract, Saes et al., DGK, Mannheim April 2011) this part of 
cTnI interacts with actin; the replacement of lysine in position 206 by glutamine abolishes 
cTnI-C-terminus/actin interaction indicating a stabilization of the activated state. 
Furthermore, K206Q as well as G203S impair transduction of the PKA dependent 
phosphorylation signal in vitro (Deng et al., 2003). This implies that PKA dependent 
phosphorylation at the cTnI-N-terminus modulates not onlyfunction of inhibitory and 
switch region, but also of the mobile domain. 
2.3.2 Mutations in TNNI3 linked to RCM 
Mutations linked to RCM occur mostly in the regulatory domain as do HCM inducing 
mutations and may share even the same locus (Table 3). Thus for example R145G induces 
FHC and R145W, RCM. Indeed RCM and HCM have some clinical as well as molecular 
characteristics in common. Both diseases show diastolic dysfunction and all RCM mutations 
investigated lead to enhanced Ca2+- sensitivity as do most of the HCM inducing mutations. 
Many of them reduce maximal tension a well as maximal actomyosin ATPase activity and 
impair inhibition (Gomes et al., 2005; Davis et al., 2008; Kobayashi & Solaro, 2006; for review 
see Parvatayar et al., 2010). Thus it is unclear how the RCM phenotype develops. But it 
indicates that the type of exchange (for example R145G HCM and R145W RCM) might be 
important for the disease development. A glycine exhibits a much smaller van der Waals 
volume, higher flexibility and higher hydrophilicity than a tryptophan at the same position 
and thus may alter interactions and dynamic properties very differently. Ca2+-regulation is 
accompanied by allosteric transitions which are dependent on dynamic properties of the 
proteins involved. Thus alteration in dynamic properties affects Ca2+ regulation and might 
determine the type of dysfunction (Lassalle, 2010). 
2.3.3 Mutations in TNNI3 linked to DCM 
The first mutation identified (autosomal recessive) is located at the very N-terminal end of 
the heart specific N-terminal arm of cTnI and leads to a conservative replacement of the 
amino acid alanine by valine, which both are hydrophobic (Table 3). However, in contrast to 
alanine, valine is branched, takes double of the van der Waals volume and has a higher 
hydropathy index. These altered physicochemical properties might produce local structure 
disturbances and therefore modify interactions. According to Murphy et al., 2004 this amino 
acid exchange affects cTnI/cTnT interaction, though no direct interaction of the N-terminal 
arm with cTnT has been described so far. There are several contacts of the non 
phosphorylated N-terminus with cTnC- N-terminal lobe and of the phosphorylated N-
terminus with the regulatory C-terminal region of cTnI. The mechanism how this mutation 
may alter cTnI/cTnI interaction is not clear. Further investigations are needed. Lately 
Carballo et al. (2009) described two new DCM mutations in cTNNI3 with an autosomal 
dominant trait leading to a severe onset of the disease. K36Q is located near constitutive 
cTnC interaction site and in the putative hinge region important for phosphorylation 
dependent movement of the cTnI-N-terminal arm. Therefor this mutation possibly might 
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affect structural integrity of the troponin complex and ß-adrenergic responsiveness. N185K 
is located within the mobile cTnI C-terminal region. In vitro both amino acid replacements 
reduce Ca2+ -sensitivity of the actomyosin ATPase and decreased maximal ATPase activity 
(Carballo et al., 2009) considered as typical for DCM. 
 
mutation disease exon reference 
Arg21Cys (R21C /R20C) HCM 3 
Barr, Seidman et al. (2001) first posted on 
URL: http: //www. cardiogenomics.org; 
Arad et al., (2005 ) Circ. 112:2805-1 ; Gomes 
et al.,(2005) JMCC 39 :754-65 
Arg141Gln (R141Q) HCM 7 
Richard et al., (2003) Circ. 107:2227-32 ; Van 
Driest et al., (2003) Circ. 108 : 445-51 
Leu144Pro (L144P) HCM 7 





Kimura et al., (1997) Nat Genet. 16:379-82. 
Takahashi-Yanaga, et al., (2000) J Biochem 
(Tokyo) 127:355-7, Elliott et al. (2000) JBC 
275:22069-74 ; Deng et al., (2001) Biochem. 
40:14593-602; Takahashi-Yanaga et al., 
(2001)JMCC 33:2095-107 ; Lang et al., (2002) 
JBC 277(4):11670-8 ; Burton et al., (2002) 
Biochem J 362:443-51 ; Lindhout et al., (2002) 
Biochem 41:7267-74 and (2005) Biochem 
44:14750-9; Kruger et al., (2005) J Physiol 564: 
347-57, Wen et al.,(2008) JBC 283: 20484-94; 
Reis et al., (2008) Pflugers Arch. 457:17-24 
Arg145Gln (R145Q) HCM 7 
Kimura et al., (1997) Nat Genet 16:379-82 ; 
Taka-hashi-Yanaga et al., (2001) JMCC 33: 
2095-107; Mogensen et al., (2004) JACC 44: 
2315-25. 
Ala157Val (A157V) HCM 7 
Richard et al., (2003) Circ. 107: 2227-32 ; 
Mogensen et al., (2004) JACC 44:2315-25; 
Brito & Madeira (2005)Rev Port Cardiol. 
24:1137-46 ; Meder et al., (2009) J Cardiol 15: 
274-8 
Arg162Trp (R162W) HCM 7 
Kimura et al., (1997) Nat Genet 16: 379-82; 
Elliott et al., (2000) JBC 275: 22069-74; 
Takahashi-Yanaga et al., (2001) JMCC 33: 
2095-107 
Arg162Gln (R162Q) HCM 7 
Van Driest et al., (2003) Circ.108: 445-51; 
Mogensen et al., (2004) JACC 44: 2315-25 ; 
Doolan et al., (2005) JMCC 2005 38: 387-93; 
Cheng et al., (2005) JACC 46:180-1; Ingles et 
al., (2005) J Med Genet. 42 :e59. 
Arg162Pro (R162P) HCM 7 
Richard et al., (2003)Circ. 2003 107: 2227-32; 
Doolan et al., (2005) JMCC 38: 387-93; Ingles 
et al., (2005) J Med Genet. 42: e59 
Ser166Phe (S166F) HCM 7 
Van Driest et al., (2003) Circ. 108: 445-51; Van 
Driest et al., (2004) JACC 44: 1903-10; 
Mogensen et al., (2004) JACC 44: 2315-25 
Lys178del (ΔK178) HCM 7 Richard et al., (2003) Circ. 107: 2227-32 
Lys183Glu (K183E) HCM 7 Mogensen et al., (2004) JACC 44: 2315-25 
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mutation disease exon reference 
Lys183del (ΔK183) HCM 7 
Kimura et al., (1997) Nat Genet. 16: 379-82; 
Kokado et al., (2000) Circ. 102: 663-9; 
Takahashi-Yanaga et al., (2001) JMCC 33: 
2095-107; Kohler et al., (2003) Physiol Gen. 
14: 117-28 ; Konno et al., (2005) J Int Med. 
258: 216-24. 
Arg186Gln (R186Q) HCM 8 
Richard et al., (2003) Circ. 107:2227-32; 
Mogensen et al., (2004) JACC 44: 2315-25 
Ile195Met (I195M) HCM 8 
Barr, Seidman et al., (2001) first posted on 
URL: http://www. cardiogenomics.org 
Asp196Asn (D196N) HCM 8 
Richard et al., (2003) Circ. 107: 2227-32; 
Mogensen et al., (2004) JACC 44: 2315-25; 
Nimura et al., (2002) Circ. 105 : 446-51 
Leu198Val (L198V) HCM 8 
Merk, Seidman et al., (2005) first posted on 
URL:http://www. cardiogenomics.org 
Leu198Pro (L198P) HCM 8 Doolan et al., (2005) JMCC 38: 387-93 
Ser199Gly (S199G) HCM 8 Mogensen et al., (2004) JACC 44: 2315-25 
Ser199Asn (S199N) HCM 8 
Mogensen et al., (2004) JACC 44: 2315-25; 
Brito & Madeira (2005) Rev Port Cardiol. 24: 
1137-46 
Glu202Gly (E202G) HCM 8 Mogensen et al., (2004) JACC 44: 2315-25 





Kimura et al., (1997) Nat Genet. 16:379-82; 
Kokado et al., (2000) Circ. 102: 663-9 ; 
Takahashi-Yanaga et al., (2001) JMCC 33: 
2095-107 ; Burton D et al., (2002) Biochem J 
362: 443-51; Kohler et al., (2003) Physiol Gen. 
14: 117-28, Deng et al., (2003) JMCC 35: 1365-
74; Tsoutsman et al., (2006) JMCC 41: 623-32; 
Nguyen et al., (2007) Int J Cardiol. 119: 245-8; 
Lam et al., (2010) JMCC 48: 1014-22 
Gly203fs (G203fs) HCM 8 
Morner et al., (2000) JMCC 32: 521-5 and 
(2003) 35: 841-9; Richard et al., (2003) Circ. 
107: 2227-32 
Arg204Cys (R204C) HCM 8 
Barr, Seidman et al., (2002) first posted on 
URL: http://www. cardiogenomics.org 
Arg204His (R204H) HCM 8 
Doolan et al., (2005) JMCC 38: 387-93; Ingles 
et al., (2005) J Med Genet. 42: e59 
Lys206Gln (K206Q) HCM 8 
Kimura et al., (1997) Nat Genet. 16:379-82; 
Taka-hashi-Yanaga et al., (2001) JMCC 33: 
2095-107; Kohler et al., (2003) Physiol Gen. 
14: 117-28; Deng et al., (2003) JMCC 35: 1365-
74 
Ala2Val (A2V) DCM, recessive 1 Murphy et al., (2004) Lancet 363: 371-2 
Lys36Gln (K36Q) DCM, dominant 3 Carballo et al., (2009) Circ. 105 : 375-82 
Asn135Lys (N135K) DCM dominant 7 Carballo et al., (2009) Circ. 105 : 375-82 
Leu144Gln (L144Q) RCM 7 
Mogensen et al., (2003) JCI 111:209-16; 
Gomes et al., (2005) JBC 280: 30909-15 
Arg145Trp (R145W) RCM 7 
Mogensen et al., (2003) JCI 111: 209-16; 
Mogensen et al., (2004) JACC 44: 2315-25; 
Gomes et al., (2005) JBC 280: 30909-15; Cheng 
(2005) J Am Coll Cardiol 46: 180-1 
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mutation disease exon reference 
Ala171Thr (A171T) R CM 7 
Mogensen et al., (2003) JCI 111: 209-16; 
Gomes et al., (2005) JBC 280: 30909-15 
Lys178Glu (K178E) RCM 7 
Mogensen et al., (2003) JCI 111: 209-16; 
Gomes et al., (2005) JBC 280: 30909-15 
Asp190His (R190H) RCM 8 
Mogensen et al., (2003) JCI 111: 209-16; 
Gomes et al., (2005) JBC 280: 30909-15 
Asp190Gly (D190G) RCM 8 Davis et al., (2008) JMCC 44: 891-904 
Arg192His (R192H) RCM 8 
Mogensen et al., (2003) JCI 111: 209-16; 
Gomes et al., (2005) JBC 280: 30909-15 
In brackets the one letter code and positions due to species specifities are given; fs designates 
frameshift. 
Table 3. Mutations in TNNI3 
In summary, there seem to be three major factors on the molecular level which help to 
understand phenotype development and might be directive for future investigations. 1) 
Mutations might severely affect affinity to other thin filament proteins and/or enhance 
susceptibility to proteolysis. In both cases structural integrity of the thin filament would be 
disturbed, which would in turn affect contractile function. It might even affect sarcomeric 
structure. 2) Mutations alter dynamical properties of the protein. Changes in dynamics 
might affect inter- and intramolecular interactions, Ca2+-regulation, ß –adrenergic 
responsiveness and PKC mediated phosphorylation and thereby may induce contractile 
dysfunction in various degrees. 3) Combinations of mutations might lead to additive or 
compensatory effects.  
3. Clinical presentation 
3.1 Diagnosis of HCM 
In 1989 (Jarcho et al., 1989) and 1990 (Geisterfer-Lowrance et al., 1990), the first “disease 
genes” have been identified in family members with inherited hypertrophic 
cardiomyopathy (HCM). This identification of disease genes has raised many expectations, 
among others in the better understanding of the molecular mechanisms of disease 
development, in a more reliable identification of patients at risk, and in new concepts of 
treatment (Keren et al.; 2008, Lippi et al., 2009; Marian, 2010; Ho, 2010a; Watkins et al, 1995; 
2011). The following paragraphs will focus on the clinical presentation of patients with 
mutations in the genes encoding troponin C, T and I (TNNC1, TNNT2, and TNNI3) in the 
context of HCM. For clinical presentation of HCM patients in general the reader is referred 
to an excellent book chapter from Fatkin et al., (2007). 
HCM is clinically suggested in patients by the presence of unexplained left ventricular 
hypertrophy (LVH, usually defined as ventricular wall thickness ≥ 15 mm or ≥ 13 mm in 
relatives of a HCM patient; Elliott et al., 2008) and a non-dilated left ventricle with preserved 
or even enhanced global systolic function (Fig.5). Diagnosis relies on the electrographic and 
echocardiographic demonstration of hypertrophy. LVH may be diffuse or more segmentally 
distributed (proximal and/or midportion of the interventricular septum, apex, anterior or 
lateral wall), but no single morphologic expression appears to be specific (Klues et al., 1995). 
In fact, differentiation of LVH secondary to HCM may be difficult from other diseases 
affecting the ventricles, e.g. hypertrophy secondary to infiltrative diseases (e.g. amyloidosis), 
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Fabry’s disease (Monserrat et al., 2007), glycogen storage disorders (Arad et al., 2005a), or 
systemic arterial hypertension. These diagnostic difficulties may rise with advanced age.  
 
 
(IVS=septum, LV/RV=left/right ventricles, Ao=aorta ascendens, LA=left atrium) 
Fig. 5. 2D and M-mode echocardiogram demonstrating severe hypertrophy (> 25 mm) of the 
septum 
Besides LVH, left ventricular outflow obstruction is one of the most suspicious features of 
this disease. Braunwald & Ebert (1962) noted first the dynamic component of this 
obstruction. Later on the systolic anterior motion (“SAM”) of the anterior leaflet of the mitral 
valve was recognized as the major contributor of left ventricular outflow obstruction and the 
more or less significant accompanying mitral regurgitation (Marian 2010). In a series of 320 
consecutive HCM patients, this obstructive pathology at resting conditions (defined as a 
gradient ≥ 50 mmHg at rest) was found in 37% of patients (Maron et al., 2006). In the 
remaining patients, 52% developed dynamic outflow gradients during exercise or 
maneuvers which decrease afterload or increase contractility. These high numbers, however, 
should be cautiously extrapolated for the general HCM population because of referral bias 
and patients selection criteria.  
Abnormal diastolic function (prolonged LV relaxation and increased LV chamber 
stiffness) is an almost universal feature of HCM. It appears that diastolic dysfunction is a 
very early manifestation of HCM, even before morphological evidence of hypertrophy 
occurs (Nagueh et al., 2001; Ho et al., 2009). Today, diastolic dysfunction is suggested if 
the ratio between early diastolic peak filling velocity (the E wave in transmitral Doppler) 
and early diastolic peak velocity of the mitral annulus (the E’ derived from tissue 
Doppler) exceeds the value 15 in the presence of normal systolic function (Fig. 6; Ommen 
et al., 2000; Paulus et al., 2007). 
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Fig. 6. Transmitral Doppler (top) and tissue Doppler (bottom) allowing quantification of the 
early diastolic peak filling velocity (E) and early diastolic peak velocity of the mitral annulus 
(E’). The ratio E/E’ is used to determine diastolic dysfunction. 
The clinical presentation of HCM patients shows a remarkable diversity: some 
individuals experience none or minor symptoms, others may develop dyspnoe at 
exercise or at rest, angina pectoris, palpitations, atrial fibrillation, dizziness, presyncope 
and syncope, fatigue or finally end stage heart failure requiring cardiac transplantation 
(Ho, 2010a).  
The changes on ECG are very variable and include left axis deviation, occurrence of Q 
waves, a positive Sokolow index for hypertrophy, conduction abnormalities, ST-T 
depression or other abnormalities, negative T waves and giant T waves (particularly 
observed in Japanese patients with apical type of HCM (Sakamoto et al., 1976). The ECG 
abnormalities may not parallel hypertrophy in all cases. In fact, ECG abnormalities are more 
frequently found in HCM patients as echocardiographic abnormalities. Konno et al. (2005) 
observed ECG abnormalities (in particular ST-T abnormalities) in about 54% of genetically 
affected, but nonhypertrophic patients at echocardiography. However, almost all of ECG 
abnormalities (perhaps except giant T waves) are unspecific, and do also occur in patients 
with advanced age for various other reasons.  
The underlying histopathology is characterized by gross cardiac hypertrophy, myocyte 
hypertrophy, disarray of cardiac cells, interstitial fibrosis, hyperplasia of the media of 
coronary arteries. The cardiac myocyte disarray (Fig. 7) appears to be a hallmark of HCM, 
not infrequently involving up to 20% of the ventricles (Maron & Roberts, 1979; Elliot & 
McKenna, 2004). 
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Fig. 7. Histology of the heart of a patient with HCM demonstrating typical disarray of the 
myocytes and myofibrils.  
3.2 Complications and general prognosis in HCM 
A major concern in the management of patients with HCM is prognosis. Sudden cardiac death 
(which may account for 50% of the disease-related death), atrial fibrillation with the risk of 
stroke, and congestive heart failure (CHF) are the leading contributors to the morbidity and 
mortality associated with HCM (Keren et al., 2008; Marian 2010). Overall, HCM is a “benign” 
disease with an annual mortality rate of 0.5-1% in unselected HCM-affected subjects (Cannan et 
al. 1995). However, sudden death may the first clinical manifestation of this disease, particularly 
in young otherwise healthy appearing subjects (Maron et al., 1996). In a meta-analysis by 
Liberthson (1996), HCM was the most frequent single cause of sudden death in children and 
young adults. This was supported by a large series of Maron (2003) who analyzed 387 young 
athletes who died suddenly, and found that HCM was the cause in 26.4%. The overall risk of 
sudden death appears to be similar in males and females (Olivotto et al., 2005), by contrast, 90% 
of 134 athletes with sudden cardiac death were males (Maron et al., 1996).  
The risk for sudden cardiac death can be effectively reduced by the prophylactic 
implantation of an internal automated defibrillator (ICD), the main problem is, however, to 
identify those who will profit from this device. So far, no single risk factor (except surviving 
cardiac arrest) has been identified which may clearly justify prophylactic ICD implantation. 
Nowadays, a more comprehensive approach is used combining informations/findings 
(family history of sudden death, severe cardiac hypertrophy, history of presynope or 
syncope, non-sustained or sustained ventricular tachycardia) (Kofflard et al., 2003; Marian 
2003; Frenneaux 2004; Marian 2010). It is a new challenge to integrate genotype testing in 
this risk assessment algorithm, although the power of genetic testing appears to be up to 
now more the identification of non-carriers in HCM families obviating the need for clinical 
screening and follow-up examinations (Keren et al., 2008; Pinto et al., 2011). The ethical, 
legal and societal implications of genetic testing for cardiac diseases in clinical practice has 
been discussed elsewhere (Tester & Ackerman, 2011). Furthermore, the pro and contra of 
genotyping in predicting prognosis in HCM has been recently discussed in Circulation (Ho, 
2010b; Landstrom & Ackerman, 2010).  
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The true penetrance of all clinical presentations is not known and may be underestimated 
because the clinical diagnosis of HCM is not robust. Furthermore, clinical findings may 
either vary over time or the disease-related abnormalities may have a variable onset during 
life. For example, progressive increase in LV wall thickness has been observed in 
adolescents and young adults with HCM, whereas wall thickness remains to be more stable 
in the elderly (Maron et al., 1986; Semsarian et al., 1997). This may, however, not be true for 
all mutations. Revera et al. (2007) re-evaluated 22 carriers with an Arg92Trp (TNNT2 gene) 
mutation after an average of 11 years. With age, left ventricular hypertrophy increased (≥ 5 
mm wall thickness, as assessed by echocardiography) in 50% of individuals. These later 
points are of particular importance since most clinical studies have a cross-sectional design, 
and prospective longitudinal studies are scarce.  
All groups are in agreement that the phenotypic heterogeneity in HCM patients/families 
cannot be explained by the genetic defect alone. Other factors must be involved including 
sex, additional disease such as arterial hypertension, and environmental factors. This 
heterogeneity is particularly striking in families with one genetic defect, but demonstrating 
phenotypes of different cardiomyopathies. For example, Menon et al. (2008) identified a 
large family with a mutation in the TNNT2 gene (Ile79Asn). This mutation affected 9 family 
members. Mutation carries showed clinically a restrictive cardiomyopathy in 2, a non-
obstructive HCM in 3, dilated cardiomyopathy in 2, a mixed cardiomyopathy in 1, and mild 
concentric hypertrophy in 1 family member. Genetic factors others than the causal 
sarcomere mutation may affect the penetrance and severity of cardiac abnormalities, 
referred as the modifier genes. In this regard, variants of the angiotensin-1 converting 
enzyme (ACE-1) gene are discussed as potential modifiers, increasing the risk for sudden 
cardiac death (Marian et al., 1993) and the severity of LVH (Lechin et al., 1995). Beside 
modifier genes, others factors must also determine the phenotype, as pressure or volume 
load, since manifestations of HCM are predominantly restricted to the LV, although the 
mutant sarcomeric protein is expressed in both ventricles. Finally, homozygous mutations 
(as it has been described for a child with a Ser179Phe mutation in the TNNT2 gene who died 
suddenly at the age of 17 (Ho et al., 2000)), or multiple mutations within the sarcomere 
protein encoding genes may cause a more severe type of HCM. For example, Girolami et al. 
(2010) identified in a cohort of 488 unrelated index HCM patients 4 patients (0.8%) who 
harbored triple mutations of the sarcomere proteins. The triple sarcomere defects were 
associated with an adverse outcome. 
Mutations in the troponin genes (TNNC1, TNNT2, TNNI3) are accounting for less than 10% 
of patients with HCM. In a large series of 197 index patients living in France, Richard et al. 
(2003) detected disease-casing mutations in 63%, whereby mutations within the TNNT2 and 
TNNI3 gene accounted for 4% each.  
3.3 TNNT2 
In MEDLINE, reports on approx. 194 HCM patients from various living areas with a 
mutation of the TNNT2 gene have been published so far (Thierfelder et al., 1994; Watkins et 
al., 1995; Forissier et al., 1996; Moolman et al., 1997; Anan et al., 1998; Elliott et al., 1999; Ho 
et al., 2000; Varnava et al., 2001; Richard et al., 2003; Van Driest et al, 2003; Garcia-Castro et 
al., 2003; Torricelli et al., 2003; An et al., 2004; Theopistou et al., 2004; Miliou et al., 2005; 
Konno et al., 2005; Capek & Skvor, 2006; Menon et al., 2008; Xu et al., 2008; Gimeno et al., 
2009). Table 4 summarizes those reports (86 families, 188 genetically affected subjects) which 
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provided at least prognostic informations and/or some data on the phenotype. The median 
age (at the time of examination) is 40 years, 56.1% are females. Maximal left ventricular wall 
thickness was less than 15 mm in 49.5% of genetically affected subjects, only in 9.7% of 
patients, the wall thickness exceeded 25 mm. The ECG was abnormal in the majority of 
affected subjects (78.8%). Congestive heart failure (CHF, NYHA class ≥ II) was present in 
42.9% of subjects. Prognostic data were available for 30 affected families, 19 lamented 
sudden cardiac death within their families. In additional 31 index patients, sudden cardiac 
death, heart transplantation or an ICD implantation was reported on 11 patients. Watkins et 
al. (1995) overlooked a series of 67 subjects over the age of 16 years who had TnT mutations. 
He noted that 24% of these individuals did not fulfill the clinical diagnostic criteria of HCM. 
The risk for disease-related death, however, was high (sudden cardiac death, death related 
to CHF). Varnava et al. (2001) investigated histologically 75 hearts with HCM. Blood 
samples from relatives and/or affected patients (before death) were available in 50 cases, 
allowing genotyping. Mutations in the TNNT2 gene were found in 9/50 patients, 8 of the 9 
patients died suddenly. The heart weight was less, but the degree of disarray was 
significantly more in those patients with a mutation of the TNNT2 gene as compared to 
mutations of other genes. Other authors confirmed this constellation “minor LVH and high 
risk for sudden cardiac death” particularly for the following mutations: Phe87Leu (Gimeno 
et al., 2009), Arg92Trp (Moolman et al., 1997), Ala104Val (Nakajima-Taniguchiet et al., 1997), 
and Lys273Glu (Fujino et al., 2002).  
3.4 TNNI3 
Reports on approx. 99 patients have been published so far (Kimura et al., 1997; Kokado et 
al., 2000; Mörner et al., 2000; Niimura et al., 2002; Richard et al., 2003; Van Driest et al., 2003; 
Mogensen et al., 2004; Arad et al., 2005b; Brito & Madeira, 2005; Doolan et al., 2005; Sheng et 
al., 2008). Table 5 summarizes the reports (41 families, 87 genetically affected subjects) which 
provided prognostic informations or some data on phenotype. The median age (at the time 
of examination) is 46 years, 55.1% are females. Maximal left ventricular wall thickness was 
less than 15 mm in 53.2% of genetically affected subjects, in none the wall thickness 
exceeded 25 mm. An abnormal ECG was observed in 90.5% of genetically affected patients. 
Congestive heart failure was present in 36.4% subjects. In 24 of 37 families, sudden cardiac 
death or cardiac arrest occurred.  
3.5 TNNC1 
Only six cases with mutations of the TNNC1 gene have been published so far (Hoffmann et 
al., 2001; Landstrom et al., 2008; Chung et al., 2011) (Table 6). The first missense mutation 
within the TNNC1 gene (Leu29Gln) was described by Hoffmann et al. (2001) in a 60 year-
old man with a moderate LV hypertrophy, ECG abnormalities and heart failure. The 
number of cases is too low to characterize a typical phenotype. Three of the 6 cases 
underwent myectomie, in a 19 year-old man, sudden cardiac death occurred.  
3.6 Prognosis in patients with mutations of the genes encoding cTnT and cTnI 
Overall, patients with mutations within the gene encoding cardiac troponin T and I are 
characterized by minor/moderate left ventricular hypertrophy, the maximal wall thickness 
of the LV does exceed 25 mm in a small percentage only. Despite the presence of 
minor/moderate LV hypertrophy, the rate of abnormal ECGs is high (> 75%). Furthermore, 
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congestive heart failure is not an infrequent complication (35-40% of the genetically affected 
patients). The rate of sudden cardiac death/arrest appears to be very high (> 30% of index 
patients or in related family members). Whereas some mutations are associated with sudden 
cardiac death at any age (e.g. the Lys183 deletion mutation in he TNNI3 gene; Kokado et al., 
2000), others are associated with disease-related death predominantly in older carriers (e.g. 
the Phe87Leu mutation within the TNNT2 gene; Gimeno et al., 2009), or at younger age (e.g. 
the Arg92Trp mutation within troponin T; Moolman et al., 1997). Of note, the degree of 
disarray of the myocytes may not parallel the magnitude of hypertrophy: Gambrin et al. 
(2008) described a 22 year old women who underwent cardiac transplantation for restrictive 
filling pattern and CHF. Histology revealed severe disarray in the absence of hypertrophy. 
Genetic analysis disclosed an Arg204His mutation in the TNNI3 gene.  
The mechanism of sudden cardiac death in patients with HCM is still under debate (Ho, 
2010 a,b). For many years, the ischemia hypothesis has been proposed, that is increased 
oxygen demand due to increased LV mass and wall stress, combined with reduced oxygen 
supply due to reduced capillary density and abnormal narrowed intramural coronary 
arteries. This balance may further deteriorate if myocardial bridging with systolic 
compression of epicardial coronary artery is present (Yetman et al., 1998). The ischemia 
hypothesis is supported by a study of Spirito et al. (2000). These authors investigated the 
relation between the magnitude of hypertrophy and mortality in 480 consecutive patients 
with HCM. Over a follow-up period of 6.5 years, 65 patients died (23 sudden death, 15 CHF-
related, 27 noncardiac cause or stroke). The risk of sudden death increased progressively 
with the wall thickness (0 per 1000 person-years for a wall thickness ≤ 15 mm, up to 18.2 per 
1000 person-years for those with a wall thickness ≥ 30 mm).  
3.7 What we can learn from patients with troponin mutations 
What can we learn from the patients with troponin mutations? One important message to 
the clinicians is that the risk of sudden cardiac death does not go along with the severity of 
left ventricular hypertrophy/wall thickness. Furthermore, sudden cardiac death may occur 
in all age groups with troponin mutations. These observations imply that other mechanisms 
than ischemia-triggered rhythm disturbances may account for the excessive risk of sudden 
cardiac death in this subgroup (and other subgroups?) of patients with HCM. In transgenic 
mice expressing the TnT-I79N (Ile79Asn) mutation, no ventricular hypertrophy or fibrosis 
was detected, but ventricular ectopy and the rate of stress-induced ventricular tachycardia 
were significantly increased (Knollmann et al, 2003). Baudenbacher et al. (2008) showed in 
this mouse model that the risk of developing ventricular tachycardia appears to be directly 
proportional to the degree of Ca2+ sensitization caused by different troponin T mutations 
(TnT-I79N, TnT-F110I, and TnT-R278C). They gave first evidence that reduction of Ca2+ -
sensitivity (by blebbistatin) in myofilaments acts “antiarrhythmic”. This work by 
Baudenbacher and coworkers clearly demonstrates that changes in the intracellular Ca2+ -
sensor cardiac troponin are associated with arrhythmias, and histological/anatomical 
changes which do often later develop in the course of hypertrophic cardiomyopathy, are not 
a prerequisite for these life-threatening arrhythmias. In our laboratory, we studied the 
effects of the cTnI-R145G mutation on adrenergic signalling in isolated rat ventricular 
cardiomyocytes (Reis et al., 2008). This mutation hinders the transduction of the 
phosphorylation signal from troponin to the thin filament. Upon adrenergic stimulation of 
the cardiomyocytes, rates of shortening and relengthening were significantly suppressed. 
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This suppression was evident in response to ß2- but not ß1-adrenergic stimulation. These 
data demonstrate that adrenoceptor-mediated signalling may be altered by troponin 
mutations. Since sudden cardiac death in patients with HCM often occurs during exercise or 
physical activity, thus conditions with increased sympathetic activity, altered adrenergic 
signalling may be a potential player in the pathogenesis of life-threatening arrhythmias. 
Many other mechanism are currently under investigation, including the role of the myocyte 
enhancer factor 2, transforming growth factor, connective tissue factor, and periostin in the 
development of hypertrophy, diastolic dysfunction, and myocardial scarring (Seidman & 
Seidman, 2011); also altered intracellular calcium handling and abnormalities in myocardial 
energetics are under discussion to participate in this complex phenotype (Ho, 2010a,b). 
Despite obvious progress, the precise link between the molecular defect and the complex 
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Ile79Asn         







n.a. n.a. n.a. n.a. 
4 SCD in 
family 





16 M n.a. n.a. n.a. n.a. n.a. SCD 
Varnava et 
al., 2001 
n=9 (1 family) 
Area: U.S.A. 
50 F1 n.a. n.a. n.a. n.a. + 
DCM, death 
at age 64 
Menon et al., 
2008 
 68 F 10 9 normal + + 
DCM, death 
at age 73 
 
 66 F1 18 10 n.a. + + -  




 58 M1 12 10 normal + + RCM type  
 53 F1 14 11 n.a. + + RCM type  
 49 F1 16 9 n.a. + + -  
 40 F1 24 8 n.a. + + -  
 48 F 14 10 n.a. - - -  
www.intechopen.com
  














ECG CHF Prognosis 




39 M n.a. 30 n.a. n.a. + - 
Van Driest et 
al., 2003 
Phe87Leu         
n=7 (1 family) 
Area: Spain 
52 F 14 n.a. n.a. + + SCD in family 
Gimeno et al., 
2009 
 39 M 13 n.a. n.a. + + “  
 40 F 14 n.a. n.a. + + “, ICD  
 30 F 18 n.a. n.a. + + “, ICD  
 30 M 27 n.a. n.a. + - “  
 29 F 25 n.a. n.a. + + “  
 9 M 12 n.a. n.a. + - “  









n=32 (3 families 






n.a. n.a. n.a. SCD in 11 p 
Watkins et al., 
1995 




56 F 14 12 n.a. + n.a. SCD in family 
Moolman et 
al., 1997 
 57 F 13 12 n.a. + n.a. “  
 41 F 12 13 n.a. + n.a. “  
 28 F 24 11 n.a. + n.a. “  
 35 F 13.8 7.5 n.a. - n.a. “  
 23 F 6 6 - + n.a. “  
 
21 M normal normal - + n.a. “  
 38 M 9 9 - + n.a. “  
 
35 F 8 8 - + n.a. “  
 28 M 7 8 - + n.a. “  
 47 F 7 7 - - n.a. “  
 27 F 6 6 - - n.a. “  
 9 F 4 4 - - n.a. “  
 28 M 8.5 8.5 - - n.a. “  
 15 F 5 5 - - n.a. “  
 11 F 7 7 - - n.a. “  
 34 F 18-20 11 n.a. + n.a. “  
 56 F 8 7 - + n.a. “  
         
n=1 (389 
unrelated p.) 
Area : U.S.A. 
27 F n.a. 32 n.a. n.a. - - 





22 M n.a. n.a.. n.a. n.a. n.a. SCD 
Varnava et 
al., 2001 
 6 F n.a. n.a. n.a. n.a. + transplant  
www.intechopen.com














ECG CHF Prognosis 




26 M n.a. n.a. n.a. n.a. n.a. SCD 
Varnava et 
al., 2001 
n=4 (1 family) 
Area: France 
43 F n.a. 19 n.a. - + CHF at 44 y 
Forissier et 
al., 1996 
 23 M n.a. 35 n.a. + + n.a  
 20 F n.a. n.a. apical + + n.a.  
 45 F n.a. 10 n.a. + - n.a.  




17 M n.a. n.a. n.a. n.a. n.a. SCD 
Varnava et 
al., 2001 
 21 F n.a. n.a. n.a. n.a. n.a. SCD  
Ala104Val         
n=4 (1 family) 
Area: Japan 




 36 F 17 6 n.a. + + SCD at age 36  




 33 F 20 12 n.a. + - -  
Phe110Ile         
n=2 (1 family) 
Area : multi-
ethnic/racial 
n.a. n.a. 17 (n=2) n.a. n.a. n.a. - 
Watkins et al., 
1995 
n=16 (6 
families) Area : 
Japan 
38 F 27 17 III + - - 
Anan et al., 
1998 
 69 F 22 14 III + - SCD in family  
 47 F 20 13 III + - SCD in family  
 87 F 9 9 IV + - -  
 48 M 10 10 IV + - -  
 42 F 11 11 normal - - -  
 64 M 23 10 II + - -  
 70 M 20 11 II + - -  
 47 F 13 13 III + - -  
 45 M 12 10 normal + - -  
 39 F 13 13 III + - -  
 24 F 11 11 IV + - -  
 56 F 19 11 II + - SCD in family  
 53 M 15 13 III + - “  
 31 F 21 12 II + - “  
 28 F 10 10 normal + - “  




28 F 32 n.a. III + - - 
Torricelli et 
al., 2003 
 48 F 21 n.a. III + n.a. -  
 82 M 15 n.a. II + n.a. -  
www.intechopen.com
  














ECG CHF Prognosis 
Lys124Asn         
n=1 (71 
unrelated p.) 
Area : China 
41 F n.a. n.a. LVH n.a. n.a. - An et al., 2004 




55 M 23 n.a. III + - - 
Torricelli et 
al., 2003 
 58 F 13 n.a. n.a. + - -  









n.a. n.a. n.a. SCD in 14 





50 F 20 n.a. III + - - 
Torricelli et 
al., 2203 
 55 M 22 n.a. III + + -  
Glu163Lys         







n.a. n.a. n.a. SCD in 0 
Watkins et al., 
1995 
Ser179Phe         
n=1 (1 family) 
Area: Kuwait 
17 M 25 11 n.a + - SCD Ho et al., 2000 
Glu244Asp         
n=1 (1 family) 
Area: multi-
ethnic/racial 
n.a. n.a. n.a. n.a. n.a. n.a. SCD in 0 
Watkins et al., 
1995 




60 F 23 n.a. n.a. n.a. n.a. - 
Garcia-Castro 
et al., 2003 
Intron 15 
G1→A         







n.a. n.a. n.a. SCD in 9 





15 M n.a. n.a. n.a. n.a. n.a. SCD 
Varnava et 
al., 2001 
Asn271Ile         
3 (1 family) 
Area: Spain 
62 M 22 n.a. n.a. + - - 
Gimeno et al., 
2009 
 36 M 14 n.a. n.a. + - -  
 31 F 9 n.a. n.a. - - -  
www.intechopen.com














ECG CHF Prognosis 
Lys273Glu         
n=8 (2 families) 
Area: Japan 
58 F 7 8 n.a. n.a. n.a. DCM features 
Fujino et al., 
2002 
 32 F 23 7 asym. n.a. n.a -  
 29 F 23 10 asym. n.a. n.a. -  
 75 F 15 13 n.a. n.a. n.a. SCD in family  
 78 F 15 11 asym. n.a. n.a. “  
 75 F 16 9 asym. n.a. n.a. “  
 49 F 20 9 asym n.a. n.a. “  
 46 M 21 10 asym n.a. n.a. “  
Arg278Cys         







n.a. n.a. n.a. SCD in 1 





57 M n.a. 20 n.a. n.a. - - 
Van Driest et 
al.,, 2003 
 66 M n.a. 15 n.a. n.a. + pacemaker  
 74 M n.a. 23 n.a. n.a. + TASH  
n=1 Area: U.K. 57 M 12 n.a. n.a. + + 
late onset 
HCM 





60 F 22 n.a. n.a. n.a. n.a. - 
Garcia-Castro 
et al., 2003 
n=8 (2 families) 
Area: Spain 
55 F 22 n.a. n.a. + + - 
Gimeno et al., 
2009 
 59 M 22 n.a. n.a. + + -  
 27 M 12 n.a. n.a. - - -  
 30 M 10 n.a. n.a. - - -  
 29 M 10 n.a. n.a. - - -  
 21 M 40 n.a. n.a. + + ICD-Impl.  
 64 M 26 n.a. n.a. + - -  
 33 M 11 n.a. n.a. + - -  
n=6 (2 families) 
Area: Greek 
40 M 20 11 asym + + SCD in family 
Theopistou et 
al., 2004 
 71 F 13 12 conc. + + “  
 41 M 10 8 normal - n.a. “  
 38 M 10 10 normal - n.a. “  
 14 F 7 8 normal - n.a. “  























ECG CHF Prognosis 




47 M n.a. 19 n.a. n.a. + ICD 




Area : Greek 
18 M n.a. n.a. LVH n.a. n.a. - 
Miliou et al., 
2005 
Arg286Cys         
n=1 (143 
unrelated p.) 
Area : Greek 
26 F n.a. n.a. LVH n.a. n.a. - 
Miliou et al., 
2005 




49 M n.a. 20 n.a. n.a. - - 
Van Driest et 
al., 2003 
 39 M n.a. 25 n.a. n.a. + myectomy  
Table 4. Mutations in the TNNT2 Gene Associated with HCM 
Number of affected patients is given (out of a group of unrelated HCM patients or families 
with HCM). Age=age at investigation if not otherwise noted; 1age at diagnosis; n.a.=data not 
available; SCD=sudden cardiac death; DCM=dilated cardiomyopathy like-type; 
RCM=restrictive cardiomyopathy like-type; CHF=congestive heart failure; 
TASH=transcoronary septal ablation; ICD=internal automated defibrillator; area=living area 
of study patients. +Left ventricular hypertrophy (LVH) is classified according to according 
to Maron et al. (1981) type I=confined to the anterior segment of the ventricular septum, 
type II=involved anterior and posterior septum, type III=involvement of both the septum 
and the free wall of the left ventricle, and type IV=regions other than the basal and anterior 
septum (e.g. apical area).  
 
Patients/Family 









ECG CHF Prognosis 




40 F n.a. n.a. apical n.a. n.a. SCD in family 
Arad et al., 
2005 
Pro82Ser         
1 pt. with late-
onset HCM 
Area: n.a. 
> 40 n.a. n.a. LVH + + n.a. 
Niimura et 
al., 2002 




41 M n.a. 25 n.a. n.a. - - 
Van Driest et 
al., 2003 
Arg145Gln         
n=1 (1 family) 
Area : U.K. 

















ECG CHF Prognosis 
Ala157Val         
n=5 (3 families) 
Area : U.K. 
n.a. n.a. n.a. n.a. + n.a. SCD in family 
Mogensen et 
al., 2004 
n=1 (1 family) 
Area: Portugal 
24 M n.a. n.a. LVH * * SCD at age 44 
Brito & 
Madeira, 2005 
Arg162Gln         
n=7 (3 families) 
Area: U.K. 






76 F n.a. 17 n.a. n.a. + myectomy 
Van Driest et 
al., 2003 
 33 M n.a. 19 n.a. n.a. + SCD in family  
         
n=3 (1 family) 
Area: Australia 
70 M n.a. n.a. n.a. n.a. n.a. n.a. 
Doolan et al., 
2005 
 44 M n.a. 10 normal - - -  
 40 M n.a. 10 normal - - -  
Arg162Pro         
n=2 (1 family) 
Area: Australia 
52 F n.a. 9 normal. - - - 
Doolan et al., 
2005 
 25 F n.a. 14 n.a. + - 
cardiac arrest 
at age 21 
 




48 F n.a. 22 n.a. n.a. + myectomy 
Van Driest et 
al., 2003 
 79 F n.a. 14 n.a. n.a. + myectomy  
 21 F n.a. 17 n.a. n.a. + myectomy  
n=1 (1 family) 
Area: U.K. 
n.a. 19 n.a. n.a. + n.a - 
Mogensen et 
al., 2004 
Lys183Glu         
n=3 (1 family) 
Area: U.K. 
n.a. n.a. n.a. n.a. + n.a - 
Mogensen et 
al., 2004 
Lys183del         
n=25 (7 families) 
Area: Japan 
65 F 13 7 I/II + n.a. SCD in family 
Kokado et al., 
2000 
 61 F 17 12 I/II + n.a. “  
 51 F 9 10 normal + n.a. “  
 46 F 20 10 I/II + n.a. “  
 36 F 16 8 I/II + n.a. “  
 48 F 7 7 normal + n.a. “  
 36 M 18 13 III + n.a. “  
 33 F 21 9 I/II + n.a. “  
 47 F 10 8 normal + n.a. “  
 27 F 13 9 III + n.a. “  
 8 M 5 5 normal - n.a. “  
 85 M 14 10 I/II + n.a. “  
 56 F 23 11 IV + n.a. “  
 48 F 13 14 IV + n.a. “  
 71 F 11 10 normal + n.a. “  
www.intechopen.com
  













ECG CHF Prognosis 
 49 M 5 9 normal + n.a. “  
 24 F 20 11 I/II + n.a. “  
 23 F 9 8 normal + n.a. “  
 66 F 11 11 normal + n.a. “  
 62 M 13 12 normal + n.a. “  
 35 M 12 11 normal - n.a. “  
 48 M 10 13 LVH + n.a. “  
 24 M 13 10 LVH + n.a. “  
 68 F 19 11 I/II + n.a. “  
 78 F 22 13 I/II + n.a. “  
Arg186Gln         
n=5 ( 2 families) 
Area: U.K. 
n.a. n.a. n.a. n.a. n.a. n.a SCD in family 
Mogensen et 
al., 2004 
Asp196Asn         
n=4 (2 families) 
Area: U.K. 






>40 n.a. LVH + + n.a. n.a. 
Niimura et 
al., 2002 
Leu198Pro         
n=1 (1 family) 
Area: Australia 
15 M n.a. 22 n.a. + - SCD at age 15 
Doolan et al., 
2005 
Ser199Gly         
n=1 (1 family) 
Area: U.K. 
n.a. n.a. n.a. apical + n.a. - 
Mogensen et 
al., 2004 
Ser199Asn         
n=8 (2 families) 
Area: U.K. 
n.a. n.a. n.a. n.a. + n.a. SCD in family 
Mogensen et 
al., 2004 
n=1 (1 family) 
Area: Portugal 
52 M n.a. n.a. LVH + - 
cardiac arrest 
at age 61 
Brito & 
Madeira, 2005 
Glu202Gly         
n=1 (1 family) 
Area: U.K. 
n.a. 19 n.a. n.a. + n.a. - 
Mogensen et 
al., 2004 
Gly203Arg         
n=2 (1 family) 
Area: U.K. 





        
n=4 (1 family) 
Area: Sweden 
71 F 9 9 normal + + - 
Mörner et al., 
2000 
 61 M 15 8 LVH + - -  
 64 M 16 14 LVH + - -  
 27 F 8 7 normal - - -  
Arg204His         
n=3 (1 family) 
Area: Australia 
37 M n.a. 17 n.a. + - 
cardiac arrest 
at age 17 
Doolan et al., 
2005 
 9 M n.a. 7 normal + - -  
 5 M n.a. 5 normal + - -  
Table 5. Mutations in the TNNI3 Gene Associated with HCM 
www.intechopen.com














ECG CHF Prognosis 





37M 18 n..a n.a. n.a. + myectomy 
Landstrom et 
al., 2008 
Leu29Gln         
n=1 Area: 
Germany 
60 M 15 15 n.a. + + n.a. 
Hoffmann et 
al. ,2001 





17 M 19 n.a. n.a. n.a. - n.a. 
Landstrom et 
al., 2008 





22 F 26 n.a. n.a. n.a. + myectomy 
Landstrom et 
al., 2008 










        
n=1(1 family) 
Area: U.S.A. 
19 M n.a. n.a. n.a. n.a. n.a. SCD 
Chung et al., 
2011 
Table 6. Mutations in the TNNC1 Gene Associated with HCM 
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